Cyclin-Dependent Kinase Inhibitor p18
"Cyclin-Dependent Kinase Inhibitor p18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An INK4 cyclin-dependent kinase inhibitor containing five ANKYRIN-LIKE REPEATS. Aberrant expression of this protein has been associated with deregulated EPITHELIAL CELL growth, organ enlargement, and a variety of NEOPLASMS.
| Descriptor ID |
D050763
|
| MeSH Number(s) |
D12.644.360.225.300 D12.776.167.187.300 D12.776.476.225.300 D12.776.624.776.355.300
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p18- Cyclin-Dependent Kinase Inhibitor p18
- Cyclin Dependent Kinase Inhibitor p18
- p18 CDK6 Inhibitor
- CDK6 Inhibitor, p18
- CDK6-Associated Protein p18
- CDK6 Associated Protein p18
- p18, CDK6-Associated Protein
- p18INK4c Protein
- Cyclin-Dependent Kinase Inhibitor 2C
- Cyclin Dependent Kinase Inhibitor 2C
- INK4C Protein
- CDKN2C Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p18".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p18".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p18" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p18" by people in Profiles.
-
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017 Sep 01; 3(9):1190-1196.
-
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017 Oct; 25(7):613-618.
-
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. Hum Pathol. 2017 02; 60:86-94.
-
Transancestral fine-mapping of four type 2 diabetes susceptibility loci highlights potential causal regulatory mechanisms. Hum Mol Genet. 2016 05 15; 25(10):2070-2081.